Intracellular HCV-RNA reduction is a proposed mechanism of action of direct-acting antivirals (DAAs), alternative to hepatocytes elimination by pegylated-interferon plus ribavirin (PR). We modeled ALT and HCV-RNA kinetics in cirrhotic patients treated with currently-used all-DAA combinations to evaluate their mode of action and cytotoxicity compared with telaprevir (TVR)+PR.
Cento, V., Nguyen, T., Di Carlo, D., Biliotti, E., Gianserra, L., Lenci, I., et al. (2017). Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. PLOS ONE, 12(5), e0177352 [10.1371/journal.pone.0177352].
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens
CENTO, VALERIA;LENCI, ILARIA;DI PAOLO, DANIELE;TETI, ELISABETTA;DI MAIO, VELIA CHIARA;SARMATI, LOREDANA;BERNARDINI, SERGIO;ANDREONI, MASSIMO;ANGELICO, MARIO;PERNO, CARLO FEDERICO;CECCHERINI SILBERSTEIN, FRANCESCA
2017-01-01
Abstract
Intracellular HCV-RNA reduction is a proposed mechanism of action of direct-acting antivirals (DAAs), alternative to hepatocytes elimination by pegylated-interferon plus ribavirin (PR). We modeled ALT and HCV-RNA kinetics in cirrhotic patients treated with currently-used all-DAA combinations to evaluate their mode of action and cytotoxicity compared with telaprevir (TVR)+PR.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.